Shionogi reports 25% profit jump, completes Torii acquisition

Shionogi reported Q1 revenue of 99.8bn yen and operating profit of 35.1bn yen, representing increases of 2.2% and 24.9% year-on-year respectively. Growth was driven by increased royalty income from its HIV franchise, with accelerating sales of Long-Acting Injectables and oral treatments.

The company completed its tender offer for Torii Pharmaceutical, integrating JT Group's pharmaceutical business to enhance R&D capabilities and domestic commercial strength.

Pipeline advances include regulatory applications for ensitrelvir in the US and Europe, Phase 2b trial initiation for RSV therapeutic S-337395, and COVID-19 vaccine S-268024 achieving its primary endpoint.